The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable
About this episode
Darshan Kulkarni discusses the challenges and risks associated with AI in drug discovery and its implications for patentability.
Send us Fan Mail "The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy reality" of AI in regulated environments. We dive deep into the three pillars of risk that can sink a biotech firm: Data Integrity: Why AI scales bad data faster than you can fix it.The Ownership Crisis: Wh...
More episodes of DarshanTalks Podcast
- Why Private Membership Associations Fail FDA Scrutiny
- The Hidden Reason Sites are Firing Recruiters
- Don’t Let Your PI Walk Away With Your Study
- Safe or Just "Not Dirty"? The Regulatory Gamble of Compounded Drugs
- "Basically Employees" Isn't a Legal Category (And the OIG Knows It)
- The Hidden Legal Risks of AI Sponsor Protocols
Explore listener stats, chart rankings, contacts and more on the DarshanTalks Podcast podcast page.